FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000952133> ?p ?o ?g. }

• W2000952133 endingPage "878" @default.
• W2000952133 startingPage "874" @default.
• W2000952133 abstract "The bronchiolitis obliterans syndrome (BOS) is the major cause of late morbidity and mortality after lung transplant (LTx). Previous studies suggest cytolytic therapy may be effective for the BOS but this therapy has not been proved effective or safe. Method A retrospective study of a predetermined treatment regimen to determine if the rate of fall in FEV1 can be reduced by corticosteroids and cytolytic therapy. Since August 1992, 10 of 65 long-term survivors of LTx (5 men, 5 women; mean age 36 ±10 years) developed BOS. All had previously had lymphocyte immune globulin, antithymocyte globulin (equine) (ATGAM sterile solution; Upjohn Pty Ltd; Sydney, Australia) induction therapy and corticosteroid avoidance for the first 7 to 10 days post-LTx. Therapy for the BOS was initiated with pulse methylprednisolone and ATGAM (aiming for an absolute CD3 count of ≤100 cells per microliter for 5 days). ATGAM therapy was initiated at a mean 657±323 days post-LTx. Subsequent follow-up has been for 310±110 days (range, 163 to 530 days). Results Nine of ten patients had a response with tolerable side effects. Preintervention, there was a linear fall in FEV1 of 0.22±0.15% predicted FEV1 per day (mean±SD) (range, 0.06 to 0.56%) compared with a postintervention linear fall of 0.036±0.019% predicted per day (range, 0 to 0.13%) (paired t test; p<0.005). This effect is sustained over the follow-up period. Conclusion The fall off in FEV1 that characterizes the BOS may be altered usefully by augmented immunotherapy. This effect can be rapid and sustained although it is neither completely arrested nor ever reversed. These data are preliminary but encourage a randomized control trial in the BOS. The bronchiolitis obliterans syndrome (BOS) is the major cause of late morbidity and mortality after lung transplant (LTx). Previous studies suggest cytolytic therapy may be effective for the BOS but this therapy has not been proved effective or safe. A retrospective study of a predetermined treatment regimen to determine if the rate of fall in FEV1 can be reduced by corticosteroids and cytolytic therapy. Since August 1992, 10 of 65 long-term survivors of LTx (5 men, 5 women; mean age 36 ±10 years) developed BOS. All had previously had lymphocyte immune globulin, antithymocyte globulin (equine) (ATGAM sterile solution; Upjohn Pty Ltd; Sydney, Australia) induction therapy and corticosteroid avoidance for the first 7 to 10 days post-LTx. Therapy for the BOS was initiated with pulse methylprednisolone and ATGAM (aiming for an absolute CD3 count of ≤100 cells per microliter for 5 days). ATGAM therapy was initiated at a mean 657±323 days post-LTx. Subsequent follow-up has been for 310±110 days (range, 163 to 530 days). Nine of ten patients had a response with tolerable side effects. Preintervention, there was a linear fall in FEV1 of 0.22±0.15% predicted FEV1 per day (mean±SD) (range, 0.06 to 0.56%) compared with a postintervention linear fall of 0.036±0.019% predicted per day (range, 0 to 0.13%) (paired t test; p<0.005). This effect is sustained over the follow-up period. The fall off in FEV1 that characterizes the BOS may be altered usefully by augmented immunotherapy. This effect can be rapid and sustained although it is neither completely arrested nor ever reversed. These data are preliminary but encourage a randomized control trial in the BOS." @default.
• W2000952133 created "2016-06-24" @default.
• W2000952133 creator A5001754592 @default.
• W2000952133 creator A5046719540 @default.
• W2000952133 creator A5085391910 @default.
• W2000952133 date "1996-04-01" @default.
• W2000952133 modified "2023-09-24" @default.
• W2000952133 title "Cytolytic Therapy for the Bronchiolitis Obliterans Syndrome Complicating Lung Transplantation" @default.
• W2000952133 cites W1965963908 @default.
• W2000952133 cites W1969107530 @default.
• W2000952133 cites W2036039626 @default.
• W2000952133 cites W2070266145 @default.
• W2000952133 cites W2071205171 @default.
• W2000952133 cites W2072400900 @default.
• W2000952133 cites W2076799432 @default.
• W2000952133 cites W2134173985 @default.
• W2000952133 cites W2238989804 @default.
• W2000952133 cites W2406252888 @default.
• W2000952133 cites W2411089254 @default.
• W2000952133 cites W4302575026 @default.
• W2000952133 doi "https://doi.org/10.1378/chest.109.4.874" @default.
• W2000952133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8635363" @default.
• W2000952133 hasPublicationYear "1996" @default.
• W2000952133 type Work @default.
• W2000952133 sameAs 2000952133 @default.
• W2000952133 citedByCount "97" @default.
• W2000952133 countsByYear W20009521332012 @default.
• W2000952133 countsByYear W20009521332013 @default.
• W2000952133 countsByYear W20009521332014 @default.
• W2000952133 countsByYear W20009521332016 @default.
• W2000952133 countsByYear W20009521332017 @default.
• W2000952133 countsByYear W20009521332018 @default.
• W2000952133 countsByYear W20009521332019 @default.
• W2000952133 countsByYear W20009521332021 @default.
• W2000952133 countsByYear W20009521332022 @default.
• W2000952133 crossrefType "journal-article" @default.
• W2000952133 hasAuthorship W2000952133A5001754592 @default.
• W2000952133 hasAuthorship W2000952133A5046719540 @default.
• W2000952133 hasAuthorship W2000952133A5085391910 @default.
• W2000952133 hasConcept C126322002 @default.
• W2000952133 hasConcept C141071460 @default.
• W2000952133 hasConcept C2776739411 @default.
• W2000952133 hasConcept C2777714996 @default.
• W2000952133 hasConcept C2780372218 @default.
• W2000952133 hasConcept C2781448352 @default.
• W2000952133 hasConcept C71924100 @default.
• W2000952133 hasConcept C90924648 @default.
• W2000952133 hasConceptScore W2000952133C126322002 @default.
• W2000952133 hasConceptScore W2000952133C141071460 @default.
• W2000952133 hasConceptScore W2000952133C2776739411 @default.
• W2000952133 hasConceptScore W2000952133C2777714996 @default.
• W2000952133 hasConceptScore W2000952133C2780372218 @default.
• W2000952133 hasConceptScore W2000952133C2781448352 @default.
• W2000952133 hasConceptScore W2000952133C71924100 @default.
• W2000952133 hasConceptScore W2000952133C90924648 @default.
• W2000952133 hasIssue "4" @default.
• W2000952133 hasLocation W20009521331 @default.
• W2000952133 hasLocation W20009521332 @default.
• W2000952133 hasOpenAccess W2000952133 @default.
• W2000952133 hasPrimaryLocation W20009521331 @default.
• W2000952133 hasRelatedWork W1966155747 @default.
• W2000952133 hasRelatedWork W1988630978 @default.
• W2000952133 hasRelatedWork W2008347710 @default.
• W2000952133 hasRelatedWork W2018523674 @default.
• W2000952133 hasRelatedWork W2156675376 @default.
• W2000952133 hasRelatedWork W2329145628 @default.
• W2000952133 hasRelatedWork W2404853076 @default.
• W2000952133 hasRelatedWork W2410342557 @default.
• W2000952133 hasRelatedWork W2417260214 @default.
• W2000952133 hasRelatedWork W3209522809 @default.
• W2000952133 hasVolume "109" @default.
• W2000952133 isParatext "false" @default.
• W2000952133 isRetracted "false" @default.
• W2000952133 magId "2000952133" @default.
• W2000952133 workType "article" @default.